iQ&A Interactive Medical Intelligence Zone for Genomic Profiling
Program Content and FAQ List
The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes national and international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine.
To ensure that the educational content of iQ&A programs will address practice gaps in clinical medicine, improve patient outcomes, and positively guide clinical practice strategies, international experts, usually in a roundtable format, will respond to questions submitted and/or generated by practitioners at CME mega-symposia, national congress, association meetings, or as part of on-line, enduring CME programs.
Questions reflecting the clinical needs of practitioners are then answered, analyzed, and discussed by international experts, who provide evidence-based and clinically relevant guidance that is independently of commercial sources or the program sponsor..

The iQ&A platform stresses:

  • Needs assessment-driven CME content
  • Evidence-based analysis
  • Expert-based guidance and consultation
  • Compliance adherence
  • Independence of content generation
  • Landmark trials
  • Association-generated practice management guidelines
  • Quality of care improvement
  • Practice gap improvement

Program Medium
Internet-based program


Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period December 21, 2016 through December 21, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 141 segments, totaling 6 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity

6.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of advances in genomics and cancer treatment.

Release Date

December 21, 2016

Expiration Date

December 21, 2018

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with or at risk for cancer.

This constituency of HCPs shall include the following audience:

  • Oncologists
  • Geneticists
  • Other specialists managing patients at risk for cancer


Registration

Participation in this iQ&A interactive Medical Intelligence Zone for Comprehensive Thrombosis Care is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals. 

Grantor Support

This activity is supported by an independent medical education grant from Roche Singapore Pte Ltd.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 6.0 AMA PRA Category 1 Credits(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials. 

Program Faculty and Disclosure

Prof. Solange Peters, MD, PhD, PD-MER
Professor of Medicine
Department of Oncology
University of Lausanne
Head, Thoracic Clinic
University Hospital
Lausanne, Switzerland

Nothing to disclose


Prof Frédérique Penault-Llorca, MD
Chief Executive Officer
Jean Perrin Comprehensive Cancer Center
Professor of Pathology
Head of the Department of Pathology and Tumor Biology
Clermont-Ferrand, France

Nothing to disclose


Prof. Luis Costa, MD, PhD
Professor of Medicine, Medical Faculty
Lisbon University
Director of the Oncology Division
Hospital de Santa Maria
Lisbon, Spain

Nothing to disclose


Prof. Jean-Yves Blay, MD, PhD
Professor of Medicine
Université Claude Bernard
Lyon, France
Scientific Director
Canceropole Lyon Rhône Alpes

Research Support and Honoraria: Novartis, Roche, GSK BMS, MSD, Pharmamar


Prof. Fabrice Barlesi, MD, PhD
Professor of Medicine
Aix Marseille University
Head, Multidisciplinary Oncology & Therapeutic Innovations Department
Assistance Publique Hôpitaux de Marseill
Aix Marseille University
Marseille, France

Nothing to disclose


Prof. Jordi Rodon, MD
Director and Clinical Head
Research Unit for Molecular Therapy of Cancer
Head, Early Clinical Drug Development Group
Vall d'Hebron Institute of Oncology
Associate Professor of Oncology
International University of Catalonia
Barcelona, Spain

Advisory Board: Leti Laboratories


Prof. Carlos Caldas, MD
Professor of Cancer Medicine
Honorary Consultant in Medical Oncology
Centre Lead for the Cambridge Experimental Cancer Medicine Centre (ECMC)
Director of the Cambridge Breast Cancer Research Unit
University of Cambridge
Cambridge, UK

Nothing to disclose


Salvatore Siena, MD
Adjunct Professor of Clinical Oncology and Hematology
University of Milan
Director, the Falck Division of Oncology
Department of Oncology
Ospedale Niguarda Ca’ Granada
Milan, Italy

Nothing to disclose


Philippe Aftimos, MD
Hematologist & Medical Oncologist
Therapeutic Innovation Leader
Medical and Scientific Coordinator
Clinical Pharmacology Unit
Institut Jules Bordet
Brussels, Belgium

Nothing to disclose


Alberto Bardelli, PhD
Associate Professor
University of Torino School of Medicine
Torino, Italy
Director, IFOM Genomics of Cancer and Targeted Therapies
Institute for Cancer Research and Treatment
Candiolo, Italy

Scientific Advisory Board: Horizon Discovery, Trovagene
Advisory Board: Novartis


Rodrigo Dienstmann, MD
Principal Investigator, Oncology Data Science (ODysSey) Group
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Computational Oncology Group
Sage Bionetworks
Seattle, Washington, USA

Nothing


Samuel Klempner, MD
Director of Precision Medicine
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA, USA

Speaker’s Bureau: FoundationOne
Advisory Board: Lilly Oncology


Prof. Christian Marth, MD, PhD
Head and Professor
Department of Obstetrics and Gynecology
Innsbruck Medical University
Innsbruck, Austria
President, Austrian Study Center for Gynecologic Oncology

Nothing to disclose


Alexander Drilon, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Honoraria: Exelixis, AstraZeneca, Genentech


Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)
Specialist in Medical Oncology
Hon. Clinical Assistant Professor
Li Ka Sing Faculty of Medicine
The University of Hong Kong

Nothing to disclose


Lia Tsimberidou, MD, PhD
Tenured Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Research Funding: Foundation Medicine


Professor Nir Peled, MD, PhD, FCCP
Pulmonologist and Medical Oncologist
Thoracic Cancer Unit
Davidoff Cancer Center
Tiqwa, Israel

Advisory Board: Foundation Medicine


Paul Mitchell, BHB, MBChB, FRACP, MD
Associate Professor
Senior Specialist
Austin Health Cancer Services
Director, North Eastern Metropolitan Integrated Cancer Services (NEMICS).
Melbourne, Australia

Nothing to disclose


Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.


Educational Objectives

Upon completion of this activity, participants will be able to: Compare and contrast the various technologies used to detect actionable mutational targets in cancer

  • Identify actionable mutational targets and targeted therapies across the spectrum of cancer
  • Explain the differences—sensitivity, specificity, and utility—between hot spot panels and hybrid capture NGS comprehensive genomic profiling
  • Detail how evidence-based deployment of genomic profiling can improve clinical outcomes in cancer
  • Identify which patient populations are appropriate candidates for NGS-based assessments and interpret and act upon results of NGS mutational testing


Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Disclaimer

Copyright © 2016 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © CMEducation Resources, LLC